Brief: Arch Biopartners' lead anti-bacterial drug candidate to enter investigator-sponsored Phase I human trial
13/04/2017 13:37
April 13 (Reuters) - Arch Biopartners Inc ARCH.V :
* Arch Biopartners' lead anti-bacterial drug candidate ab569
to enter investigator-sponsored Phase I human trial
* Arch Biopartners- Arch has initiated GMP manufacturing of
AB569 drug product that is required for trial
Source text for Eikon: ID:nCCN8ypRW2
Further company coverage: ARCH.V
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide